Back

A new nanoDSF approach to anti-tubulin compounds screening revealed novel MTAs among approved drugs.

Baksheeva, V. E.; La Rocca, R.; Leloup, L.; Souberan, A.; Berges, R.; Allegro, D.; Derviaux, C.; Pasquier, E.; Roche, P.; Morelli, X.; Devred, F.; Tchoghandjian, A.; Tabouret, E.; Golovin, A. V.; Tsvetkov, P. O.

2024-12-26 cancer biology
10.1101/2024.12.26.630395 bioRxiv
Show abstract

Microtubule Targeting Agents (MTAs) constitute a vital category of tubulin-binding compounds, deployed across anticancer therapies. Despite the array of MTA drugs developed by pharmaceutical entities, the quest for novel efficacious molecules continues unabated. We unveil an innovative in vitro MTA screening methodology employing nano differential scanning fluorimetry (nanoDSF), presenting distinct advantages over known assays. This novel approach not only assesses compound-tubulin binding but also quantitatively analyzes their impact on tubulin polymerization. Proposed nanoDSF assay was rigorously validated using the Prestwick Chemical Library, which encompasses 1,520 approved compounds, successfully identifying all previously known MTAs. Furthermore, this screening has unearthed potential anti-tubulin agents among drugs currently utilized for non-related medical conditions, offering insights into their mechanisms of action in inhibiting cancer cell proliferation and/or inducing cytotoxicity. These discoveries herald new opportunities for drug repositioning involving the newly identified MTAs and substantially streamline the process of screening extensive chemical libraries for MTAs featuring novel chemical structures.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.